Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 5:30 AM ET

Date/Time Source News Release
01/17/2025 05:19 AM EST PR Newswire XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
01/14/2025 04:37 PM EST GlobeNewswire Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
01/13/2025 07:04 PM EST Business Wire XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
12/23/2024 09:00 AM EST GlobeNewswire XBiotech Pauses Rheumatology program
06/18/2024 11:35 AM EDT GlobeNewswire XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
01/04/2024 09:00 AM EST GlobeNewswire XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
11/14/2023 09:00 AM EST GlobeNewswire Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
09/26/2023 09:00 AM EDT GlobeNewswire XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
08/30/2023 09:00 AM EDT GlobeNewswire XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
08/08/2023 11:47 AM EDT GlobeNewswire XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
Page